A Surge in M&A Activity Puts Sellas Life Sciences in the Spotlight

Sellas Life Sciences nears pivotal Phase 3 AML data, fueling acquisition speculation after Merck's deal. Stock is volatile but up ~269% YTD.

The oncology sector is witnessing a significant wave of consolidation, drawing increased investor attention to companies like Sellas Life Sciences. A recent high-premium acquisition by Merck of the rival firm Terns Pharmaceuticals has reignited market debate about the value of specialized biotech pipelines, with Sellas emerging as a notable participant due to its advanced cancer research programs.

Clinical Progress and Market Speculation

The fundamental investment thesis for Sellas centers on its clinical-stage assets. The company’s lead candidate, Galinpepimut-S (GPS), is currently being evaluated in a Phase 3 trial known as REGAL for the treatment of Acute Myeloid Leukemia (AML). Critical trial progress has been made, with 72 of the 80 events required for the final analysis already recorded as of the end of December 2025. This milestone places the firm on the cusp of releasing pivotal data that will determine the commercial future of GPS.

Market observers view Merck's strategic purchase as a catalyst, signaling renewed interest in developers of blood cancer therapeutics. In subsequent investor discussions, Pfizer is frequently cited as a potential suitor that could benefit from acquiring Sellas's development pipeline.

Valuation Dynamics and Upcoming Catalysts

Further bolstering expectations is the SLS009 program, which has demonstrated promising survival rates in a Phase 2 study involving AML patients. The current market sentiment also receives support from a positive rating issued by the analysis platform Zacks. Despite this, the stock exhibits notable volatility. In the latest trading session, shares retreated by almost 10% to €3.92, though they maintain a substantial year-to-date gain of approximately 269%.

The primary focus for all market participants now rests squarely on the final results from the REGAL study. This data set represents the most significant variable for the company's medium-term trajectory and will be a major factor in determining whether Sellas transitions from being a subject of takeover speculation to a formal acquisition target.